NEW YORK (360Dx) – Chembio Diagnostics said today it has received US Food and Drug Administration emergency use authorization (EUA) for its DPP Zika System.

The authorization makes the test available for use in high- and moderate-complexity CLIA-certified laboratories.

Under the EUA, the diagnostic can be used to test subjects meeting Centers for Disease Control and Prevention Zika virus clinical and/or epidemiological criteria. The system uses the company's DPP Micro Reader to detect Zika virus IgM antibodies in fingerstick whole blood.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.


This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.